Perinatal necrotizing enterocolitis
diseaseOn this page
Also known as enterocolitis necrotizingenterocolitis, necrotizingnecrotizing enterocolitisnecrotizing enterocolitis in foetus or newborn
Summary
Perinatal necrotizing enterocolitis (MONDO:0004639) is a disease and 158 clinical trials. Top therapeutic interventions include melatonin, pentoxifylline, and acetylcysteine. A subtype of necrotizing enterocolitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 158
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | perinatal necrotizing enterocolitis |
| Mondo ID | MONDO:0004639 |
| DOID | DOID:8677 |
| SNOMED CT | 397729009 |
| UMLS | C4082937 |
| MedGen | 906305 |
| GARD | 0024078 |
| Is cancer (heuristic) | no |
Also known as: enterocolitis necrotizing · enterocolitis, necrotizing · necrotizing enterocolitis · necrotizing enterocolitis in foetus or newborn
Disease family
This is a subtype of necrotizing enterocolitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › necrotizing enterocolitis › perinatal necrotizing enterocolitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 158.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 114 |
| PHASE2 | 13 |
| PHASE3 | 11 |
| PHASE1 | 7 |
| PHASE1/PHASE2 | 5 |
| PHASE4 | 4 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04050488 | PHASE4 | UNKNOWN | Zinc Supplementation on Very Low Birth Weight Infant |
| NCT04304807 | PHASE4 | COMPLETED | Effect of Melatonin on Feeding Intolerance and Incidence of Necrotizing Enterocolitis in Preterm Infants |
| NCT05311228 | PHASE4 | COMPLETED | The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant |
| NCT06202911 | PHASE4 | UNKNOWN | Effect of Oral N-Acetyl Cysteine in Prevention of Necrotizing Enterocolitis in Preterm Neonates With Feeding Intolerance |
| NCT03797157 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Human Milk Fortification in Extremely Preterm Infants |
| NCT06810154 | PHASE3 | NOT_YET_RECRUITING | Multi-strain Probiotics to Prevent Necrotizing Enterocolitis in Very Preterm Infants |
| NCT00254176 | PHASE2/PHASE3 | UNKNOWN | Cysteine Supplementation in Critically Ill Neonates |
| NCT00707785 | PHASE3 | COMPLETED | Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis |
| NCT01315821 | PHASE3 | UNKNOWN | Effect of Saccharomyces Boulardii on Necrotizing Enterocolitis in Very Low Birth Weight Infants |
| NCT01340469 | PHASE3 | COMPLETED | Effect of Oral Probiotic Supplementation on The Rate of Hospital Acquired Infection and Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants |
| NCT01531179 | PHASE3 | COMPLETED | Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants |
| NCT01868737 | PHASE3 | COMPLETED | Probiotics in the Management of Necrotizing Enterocolitis in HIV-exposed Premature Infants |
| NCT02650869 | PHASE3 | COMPLETED | Role of Probiotics for Prevention of NEC in Preterm VLBW Infants |
| NCT03431558 | PHASE3 | UNKNOWN | Bovine Lactoferrin and Neonatal Survival in Low Birth Weight Babies. |
| NCT03978000 | PHASE3 | UNKNOWN | IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study |
| NCT04696003 | PHASE3 | UNKNOWN | Treatment of Classic Mid-trimester PPROM by Means of Continuous Amnioinfusion |
| NCT06422000 | PHASE3 | COMPLETED | Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis |
| NCT05279664 | PHASE2 | ACTIVE_NOT_RECRUITING | RIC-NEC Randomized Controlled Trial |
| NCT06315738 | PHASE1/PHASE2 | RECRUITING | Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC) |
| NCT00271336 | PHASE2 | UNKNOWN | Pentoxifylline in the Treatment of NEC in Premature Neonates |
| NCT00437567 | PHASE2 | UNKNOWN | Prebiotics in the Prevention of Necrotizing Enterocolitis |
| NCT00540033 | PHASE2 | TERMINATED | Probiotics Reduce Incidence of Necrotizing Enterocolitis for Very Low Birth Weight Infants |
| NCT00616876 | PHASE2 | COMPLETED | Lactulose Supplementation in Premature Infants |
| NCT00621192 | PHASE1/PHASE2 | COMPLETED | Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections |
| NCT01441427 | PHASE1/PHASE2 | COMPLETED | Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial |
| NCT01603368 | PHASE2 | COMPLETED | Prophylactic Probiotics to Extremely Low Birth Weight Prematures |
| NCT01674478 | PHASE2 | COMPLETED | Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies |
| NCT01745510 | PHASE1/PHASE2 | COMPLETED | Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates |
| NCT01805206 | PHASE2 | WITHDRAWN | Prediction of NEC With Urinary iFABP |
| NCT01958320 | PHASE2 | COMPLETED | Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus |
| NCT02472769 | PHASE2 | COMPLETED | IBP-9414 for the Prevention of Necrotizing Enterocolitis |
| NCT02784821 | PHASE2 | COMPLETED | Antibiotic Dysbiosis in Preterm Infants |
| NCT02796703 | PHASE2 | UNKNOWN | Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis |
| NCT04541771 | PHASE2 | UNKNOWN | The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants |
| NCT05033639 | PHASE1/PHASE2 | COMPLETED | Efficacy Of Oral Melatonin To Prevent Necrotizing Enterocolitis |
| NCT00840983 | PHASE1 | COMPLETED | Effects of Delayed Cord Clamping in Very Low Birth Weight Infants |
| NCT01222585 | PHASE1 | COMPLETED | Metronidazole Pharmacokinetics (PK) in Premature Infants |
| NCT01954017 | PHASE1 | COMPLETED | STP206 for the Prevention of Necrotizing Enterocolitis (NEC) |
| NCT02050971 | PHASE1 | UNKNOWN | Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates |
| NCT02405637 | PHASE1 | UNKNOWN | Simulated Amniotic Fluid In Preventing Feeding Intolerance and Necrotizing Enterocolitis VLBW Neonates |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MELATONIN | 4 | 2 |
| PENTOXIFYLLINE | 4 | 2 |
| ACETYLCYSTEINE | 4 | 1 |
| AMPICILLIN | 4 | 1 |
| AZITHROMYCIN | 4 | 1 |
| CEFAZOLIN | 4 | 1 |
| CITRIC ACID | 4 | 1 |
| DEXTROSE | 4 | 1 |
| FISH OIL | 4 | 1 |
| INULIN | 4 | 1 |
| LACTULOSE | 4 | 1 |
| MEROPENEM | 4 | 1 |
| NEOMYCIN | 4 | 1 |
| RETINOL | 4 | 1 |
| ZINC SULFATE | 4 | 1 |
| ARGININE | 3 | 1 |
| BIFIDOBACTERIUM SPP. | 3 | 1 |
| CHONDROITIN SULFATE | 3 | 1 |
| CHONDROITIN SULFATE SODIUM | 3 | 1 |
| DOCONEXENT | 3 | 1 |
| FRAMYCETIN | 3 | 1 |
| L-CITRULLINE | 3 | 1 |
| MALTODEXTRIN | 3 | 1 |
| SENNA | 3 | 1 |
| CHEMBL4299381 | 0 | 1 |
| CHEMBL423707 | 0 | 1 |
| CHEMBL3754093 | 0 | 1 |
| CHEMBL4299247 | 0 | 1 |
| CHEMBL4439413 | 0 | 1 |
| 17 | 0 | 1 |